Outcomes of early switching from intravenous to oral antibiotics on medical wards

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 188-199

  Mertz, Dominik ^a   Koller, Michael ^b   Haller, Patricia ^a   Lampert, Markus L ^a,c   Plagge, Herbert ^a   Hug, Balthasar ^a   Koch, Gian ^a   Battegay, Manuel ^a   Flückiger, Ursula ^a   Bassetti, Stefano ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d NONE   (Switzerland)

Author keywords

Antimicrobials; Guidelines; Internal medicine; Policy; Stewardship

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFEPIME; CEFTRIAXONE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHECKLIST; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; INFECTION; INTERVENTION STUDY; LENGTH OF STAY; MAJOR CLINICAL STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SCORING SYSTEM; SEASONAL VARIATION; TREATMENT DURATION; TREATMENT INDICATION; WINTER;

ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 67249145087     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp131     Document Type: Article

References (67)

1. Burke JP. Infection control - a problem for patient safety. N Engl J Med 2003; 348: 651-6.
2. Shlaes DM, Gerding DN, John JF Jr et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-99.
3. Fridkin SK, Steward CD, Edwards JR et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29: 245-52.
4. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43: 459-65.
5. Davey P, Brown E, Fenelon L et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006; 12: 211-6.
6. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-64.
7. Petrak RM, Sexton DJ, Butera ML et al. The value of an infectious diseases specialist. Clin Infect Dis 2003; 36: 1013-7.
8. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
9. Ramsay C, Brown E, Hartman G et al. Room for improvement: A systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003; 52: 764-71.
10. Rojo D, Pinedo A, Clavijo E et al. Analysis of risk factors associated with nosocomial bacteraemias. J Hosp Infect 1999; 42 135-41.
11. Ramirez JA, Vargas S, Ritter GW et al. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54.
12. Sevinc F, Prins JM, Koopmans RP et al. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital. J Antimicrob Chemother 1999; 43: 601-6.
13. Ahkee S, Smith S, Newman D et al. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: A 6-month prospective study. Pharmacotherapy 1997; 17: 569-75.
14. Laing RB, Mackenzie AR, Shaw H et al. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards. J Antimicrob Chemother 1998; 42: 107-11.
15. Rhew DC, Tu GS, Ofman J et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: A meta-analysis. Arch Intern Med 2001; 161: 722-7.
16. von Gunten V, Amos V, Sidler AL et al. Hospital pharmacists' reinforcement of guidelines for switching from parenteral to oral antibiotics: A pilot study. Pharm World Sci 2003; 25: 52-5.
17. McLaughlin CM, Bodasing N, Boyter AC et al. Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: An intervention study. QJM 2005; 98: 745-52.
18. MacGregor RR, Graziani AL. Oral administration of antibiotics: A rational alternative to the parenteral route. Clin Infect Dis 1997; 24: 457-67.
19. van Zanten AR, Engelfriet PM, van Dillen K et al. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 2003; 7: R184-90.
20. Pestotnik SL, Classen DC, Evans RS et al. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes. Ann Intern Med 1996; 124: 884-90.
21. Hamilton-Miller JM. Switch therapy: The theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clin Microbiol Infect 1996; 2: 12-9.
22. Fraser GL, Stogsdill P, Dickens JD Jr et al. Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med 1997; 157: 1689-94.
23. Hitt CM, Nightingale CH, Quintiliani R et al. Streamlining antimicrobial therapy for lower respiratory tract infections. Clin Infect Dis 1997; 24 Suppl 2: S231-7.
24. Duncan RA. Controlling use of antimicrobial agents. Infect Control Hosp Epidemiol 1997; 18: 260-6.
25. Pablos AI, Escobar I, Albinana S et al. Evaluation of an antibiotic intravenous to oral sequential therapy program. Pharmacoepidemiol Drug Saf 2005; 14: 53-9.
26. Ho BP, Lau TT, Balen RM et al. The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: A pre- and post-intervention study. BMC Health Serv Res 2005; 5: 48.
27. Martinez MJ, Freire A, Castro I et al. Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion. Pharm World Sci 2000; 22: 53-8.
28. Fischer MA, Solomon DH, Teich JM et al. Conversion from intravenous to oral medications: Assessment of a computerized intervention for hospitalized patients. Arch Intern Med 2003; 163: 2585-9.
29. Angeli P, Guarda S, Fasolato S et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: Similar efficacy at lower cost. Aliment Pharmacol Ther 2006; 23: 75-84.
30. Lee RW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 2007; 12: 111-6.
31. Fine MJ, Stone RA, Lave JR et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: A randomized controlled trial. Am J Med 2003; 115: 343-51.
32. Marrie TJ, Lau CY, Wheeler SL et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-55.
33. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161: 848-50.
34. Oosterheert JJ, Bonten MJ, Schneider MM et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: Multicentre randomised trial. BMJ 2006; 333 1193.
35. Senn L, Burnand B, Francioli P et al. Improving appropriateness of antibiotic therapy: Randomized trial of an intervention to foster reassessment of prescription after 3 days. J Antimicrob Chemother 2004; 53: 1062-7.
36. Vogtlaänder NP, Van Kasteren ME, Natsch S et al. Improving the process of antibiotic therapy in daily practice: Interventions to optimize timing, dosage adjustment to renal function, and switch therapy. Arch Intern Med 2004; 164: 1206-12.
37. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-83.
38. de Groot V, Beckerman H, Lankhorst GJ et al. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003; 56: 221-9.
39. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30.
40. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 Suppl 4: IV1-64.
41. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
42. Solomkin JS, Reinhart HH, Dellinger EP et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996; 223: 303-15.
43. Wacha H, Warren B, Bassaris H et al. Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections. Surg Infect (Larchmt) 2006; 7: 341-54.
44. Starakis I, Karravias D, Asimakopoulos C et al. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral) + metronidazole (intravenous/oral) with ceftriaxone (intravenous) + metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Int J Antimicrob Agents 2003; 21: 49-57.
45. Fernandez-Sabe N, Carratala J, Dorca J et al. Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections. Eur J Clin Microbiol Infect Dis 2003; 22: 185-7.
46. Terg R, Cobas S, Fassio E et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: Results of a multicenter, randomized study. J Hepatol 2000; 33: 564-9.
47. Tuncer I, Topcu N, Durmus A et al. Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis. Hepatogastroenterology 2003; 50: 1426-30.
48. Vidal L, Paul M, Ben-Dor I et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004; issue 4: CD003992.
49. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-11.
50. Marra CA, Frighetto L, Quaia CB et al. A new ciprofloxacin step-down program in the treatment of high-risk febrile neutropenia: A clinical and economic analysis. Pharmacotherapy 2000; 20: 931-40.
51. Lutters M, Harbarth S, Janssens JP et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 2004; 52: 112-6.
52. Di Giammarino L, Bihl F, Bissig M et al. Evaluation of prescription practices of antibiotics in a medium-sized Swiss hospital. Swiss Med Wkly 2005; 135: 710-4.
53. Mol PG, Wieringa JE, Nannanpanday PV et al. Improving compliance with hospital antibiotic guidelines: A time-series intervention analysis. J Antimicrob Chemother 2005; 55: 550-7.
54. Schouten JA, Hulscher ME, Natsch S et al. Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: A qualitative study. Qual Saf Health Care 2007; 16: 143-9.
55. Halm EA, Switzer GE, Mittman BS et al. What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med 2001; 16: 599-605.
56. Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998; 317: 465-8.
57. Bugnon-Reber A, de Torrente A, Troillet N et al. Antibiotic misuse in medium-sized Swiss hospitals. Swiss Med Wkly 2004; 134: 481-5.
58. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
59. Dunn AS, Peterson KL, Schechter CB et al. The utility of an in-hospital observation period after discontinuing intravenous antibiotics. Am J Med 1999; 106: 6-10.
60. Boyter AC, Stephen J, Fegan PG et al. Why do patients with infection remain in hospital once changed to oral antibiotics? J Antimicrob Chemother 1997; 39: 286-8.
61. Nathan RV, Rhew DC, Murray C et al. In-hospital observation after antibiotic switch in pneumonia: A national evaluation. Am J Med 2006; 119: 512.e1-7.
62. Beumont M, Schuster MG. Is an observation period necessary after intravenous antibiotics are changed to oral administration? Am J Med 1999; 106: 114-6.
63. Ehrenkranz NJ, Nerenberg DE, Shultz JM et al. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: Effect on shortening patient stay. Infect Control Hosp Epidemiol 1992; 13: 21-32.
64. Przybylski KG, Rybak MJ, Martin PR et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 1997; 17: 271-6.
65. Ramirez JA, Srinath L, Ahkee S et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-6.
66. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 995; 29: 561-5.
67. Fine MJ, Medsger AR, Stone RA et al. The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157: 47-56.